Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for TP-05 in Lyme disease. The expected timing is based on the latest available company guidance and may change.
Carpo trial. 2/22/4- Topline data reported. 2/25/25- Confirmed planned regulatory path forward including Ph2 study involving hundreds of patients & Ph3 prevention study. 8/6/25- Initiate study in 2026. 11/04/25:- Company reiterated plan to initiate the Phase 2 Lyme disease prevention study in 2026. 02/23/26:- Phase 2 Lyme disease prevention study initiation expected in Q2 2026. 03/31/26:- Phase 2 Calliope trial first patient dosed; enrollment completes 2026 tick season; topline results H1 2027. 05/06/26:- Calliope Ph2 trial progress reiterated; topline data remains expected in H1 2027. 08/06/26:- Calliope Ph2 enrollment completed. Topline data expected in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.